Donor immune cells take on tough T-Cell cancers in new trial
NCT ID NCT06514794
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This phase 2 trial tests a one-time infusion of WU-CART-007, a CAR-T cell therapy made from healthy donor cells, in 125 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to see if it can wipe out cancer cells completely, including those too few to detect with standard tests. Participants must be at least 6 months old and in fairly good health aside from their cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WU-CART-007 (a type of CAR-T cell therapy made from donor cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat T-cell leukemia or lymphoma, potentially leading to long-term remission.
- What could go wrong
- This is an early-phase trial with only 125 participants, so results may not apply to everyone. CAR-T therapies can cause serious side effects like cytokine release syndrome or nervous system problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Los Angeles
RECRUITINGLos Angeles, California, 90027, United States
-
Children's Hospital of Atlanta
RECRUITINGAtlanta, Georgia, 30329, United States
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19390, United States
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
-
Colorado Blood Cancer Institute
RECRUITINGDenver, Colorado, 80218, United States
-
H. Lee Moffitt Cancer Center and Research Institute Hospital
RECRUITINGTampa, Florida, 33612, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Oncology Hematology Care
RECRUITINGCincinnati, Ohio, 45226, United States
-
Peter Mac Callum Cancer Institute
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Royal Children's Melbourne
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Sarah Cannon Transplant and Cellular Therapy Methodist Hospital
RECRUITINGSan Antonio, Texas, 78229, United States
-
Sarah Cannon, Virginia Oncology Associates
RECRUITINGNorfolk, Virginia, 23502, United States
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
-
TriStar Bone Marrow Transplant / Sarah Cannon Transplant & Cellular Therapy
RECRUITINGNashville, Tennessee, 37203, United States
-
Washington University Saint Louis
RECRUITINGSt Louis, Missouri, 63108, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug missile tame Hard-to-Treat leukemia?
- Personalized chemo dosing may boost survival in kids with High-Risk leukemia
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Engineered immune cells take aim at stubborn blood cancers
- Double-Barreled immune attack aims to wipe out T-ALL
- New drug combo aims to make stem cell transplants safer for blood cancer patients